2026年上半年，英派药业-B（07630）实现营收1.05亿元，同比增长316.8%。同期，经调整净亏损（非香港财务报告准则计量）为0.21亿元，较去年同期的0.56亿元显著收窄62.6%。公司毛利率为90.8%，上年同期为97.7%；经营活动所得现金流净额为0.24亿元，较上年同期的0.30亿元减少0.06亿元。
在成本结构方面，报告期内，研发投入约0.98亿元，同比增加13.1%，主要系产品管线开发费用增长所致。销售及分销开支为0.23亿元，上年同期该指标约为0.05亿元。公司在公告中提及，本期药品销售收入约0.70亿元，主要来自核心产品塞纳帕利销量增长，一并带动该业务板块同比增长877.8%；许可收入则同比增长至0.35亿元，增幅约93.6%。
高管解读： 英派药业-B执行董事兼首席执行官蔡遂雄博士：“本人谨代表董事会衷心感谢股东及业务合作伙伴一直以来的信任及支持，亦感谢雇员的勤勉、奉献、忠诚及诚信。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.